Need for X-ray Dose Monitoring

Navigation
About the project

     The deleterious effects of ionizing radiation are well documented and include both stochastic and deterministic effects.(1) In the past, the primary concern during diagnostic x-ray procedures has been for stochastic long-term effects such as carcinogenesis.

      Recently, there has been increasing concern for the short-term acute effects resultant from high doses of radiation associated with long interventional procedures which use fluoroscopic guidance. These acute effects are deterministic and generally have a threshold below which the effect is not observed. Effects which have been documented include epilation and serious skin injuries such as moist desquamation and tissue necrosis. (2)

      To make the medical community aware of this potential for severe acute effects, the FDA has issued several advisories which recommend the determination of radiation dose, (3-5) explaining that “the patient’s medical record should contain an unambiguous identification of those areas of the patient’s skin that received an absorbed dose that may approach or exceed the selected threshold.”

 

References:

  1. Wagner LK, Eifel PJ and Geise RA.: Potential biological effects following high x-ray dose interventional procedures. J of Vascular and Interventional Radiology 5: 71-84, 1994

  2. Shope TB: Radiation induced skin injuries from fluoroscopy. Radiology Vol. 197(P) Supplement, p 449 and Radiographics September 1996.

  3. FDA Avoidance of serious x-ray induced skin injuries to patients during fluoroscopically-guided procedures. US Food and Drug Administration, Rockville, MD. September 1994.

  4. FDA Public Health Advisory: Avoidance of serious x-ray induced skin injuries to patients during fluoroscopically-guided procedures. US Food and Drug Administration, Rockville, MD, September 30, 1994.

  5. FDA Recording information in the patient's medical record that identifies the potential for serious x-ray induced skin injuries following fluoroscopically-guided procedures US Food and Drug Administration, Rockville, MD, March 1995.

 

.

.